electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
11 Janeiro 2022 - 10:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine company, today announced the launch of an e-commerce shop
for patients residing in the United States. The site, which can be
accessed through www.gammacore.com, allows patients to complete a
telehealth consult for a prescription and purchase gammaCore
Sapphire™, a non-invasive vagus nerve stimulator (nVNS) device,
online.
The online store offers therapy to patients for
FDA-cleared indications like migraine and cluster headache. The
store platform is powered by Vytal, LLC and allows patients to
obtain a prescription via telehealth consult, purchase the therapy
directly from the site, have a member of the U.S. electroCore
customer service team provide post-purchase video conference
training, and receive the device at their doorstep.
“The launch of an online store is a tremendous
step forward in our company’s cash pay, direct-to-consumer
strategy,” stated Joshua Lev, Chief Strategy Officer at
electroCore. “More and more patients are utilizing online channels
to manage their health, and the launch of our new online store
builds on the trend of patients taking control of their healthcare.
We are very excited to offer patients the ability to obtain nVNS
therapy from the comfort of their home. The new functionality
provides direct access to millions of migraine and cluster headache
sufferers who can benefit from gammaCore nVNS therapy.”
“We are thrilled to be a part of electroCore’s
direct-to-consumer initiative to treat migraines and cluster
headaches. Our end-to-end solution for patient access to gammaCore
allows a seamless patient experience that should help patients
access this unique, proven therapy,” said Jerry Gross, Founder and
CEO of Vytal.About Vytal, LLC.Vytal is a
healthcare technology company offering comprehensive, compliant
technology solutions that enable manufacturers, pharmacies,
provider networks, wellness ecommerce companies, and virtual health
platforms to manage, grow, and scale their operations. Vytal's
data-driven direct-to-consumer ecommerce platform enables
healthcare manufacturers to reach more patients and boost brand
awareness. For more information visit https://www.vytal.care.
About electroCore,
Inc.electroCore, Inc. is a commercial stage bioelectronic
medicine company dedicated to improving patient outcomes through
its non-invasive vagus nerve stimulation therapy platform,
initially focused on the treatment of multiple conditions in
neurology. The company's current indications are the preventive
treatment of cluster headache and migraine, the acute treatment of
migraine and episodic cluster headache, the acute and preventive
treatment of migraines in adolescents, and paroxysmal hemicrania
and hemicrania continua in adults.
For more information, visit
www.electrocore.com.
About
gammaCoreTMgammaCoreTM (nVNS) is the
first non-invasive hand-held medical therapy applied at the neck as
an adjunctive therapy to treat migraine and cluster headache
through the utilization of a mild electrical stimulation to the
vagus nerve that passes through the skin. Designed as a portable
easy-to-use technology, gammaCore can be self-administered by
patients, as needed, without the potential side effects associated
with commonly prescribed drugs. When placed on a patient’s neck
over the vagus nerve, gammaCore stimulates the nerve’s afferent
fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA-cleared in the United
States for adjunctive use for the preventive treatment of cluster
headache in adult patients, the acute treatment of pain associated
with episodic cluster headache in adult patients, and the acute and
preventive treatment of migraine in adolescent (ages 12 and older)
and adult patients. gammaCore is CE-marked in the European Union
for the acute and/or prophylactic treatment of primary headache
(Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and
Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if
they:
- Have an active implantable medical device, such as a pacemaker,
hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone
screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Safety and efficacy of gammaCore have not been
evaluated in the following patients:
- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the
neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
Please refer to the gammaCore Instructions for
Use for all important warnings and precautions before using or
prescribing this product.
For more information, please visit
www.gammacore.com.
Forward-Looking StatementsThis
press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects and clinical and product development plans; its pipeline
or potential markets for its technologies; the timing, outcome and
impact of regulatory, clinical and commercial developments; the
Company’s business prospects in the United States (including its
e-commerce initiative) and other new markets and other statements
that are not historical in nature, particularly those that utilize
terminology such as "anticipates," "will," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, the potential impact and
effects of COVID-19 on the business of electroCore, electroCore’s
results of operations and financial performance, and any measures
electroCore has and may take in response to COVID-19 and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Investors:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
or
Media Contact:Jackie
DorskyelectroCore908-313-6331Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024